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Background
Strict glycemic control (SGC) decreased mortality and 
morbidity of ICU patients in two randomized controlled 
trials (RCTs) [1,2]. Five successive RCTs, however, failed 
to show beneﬁ   t of SGC [3-7], with one trial even 
suggesting SGC to cause harm since it was associated 
with an unexpected higher late mortality rate [6].
After the publication of the ﬁ  rst RCT on SGC [1], the 
ICU community seemed divided on the best method of 
glycemic control. On the one hand, study results were 
criticized: that is, it was suggested that the original study 
results lacked generalizability, at least in part because of 
the fact that it was a single-center study, and because 
patients frequently received parenteral calories, which 
was not common practice. On the other hand, several 
professional associations adopted the strategy by propos-
ing guidelines, and it was stated that hyperglycemia 
should no longer be tolerated [8]. As a consequence, 
many ICUs implemented some form of glycemic control, 
although frequently the applied regimens tolerated 
higher blood glucose levels than those used in the SGC 
strategy as studied in the original trial [1]. After publica-
tion of the second RCT on SGC, which showed less 
strong though still signiﬁ  cant beneﬁ  ts of SGC [2], the 
community continued to propagate glycemic control 
with insulin [9]. Since the publication of ﬁ  ve successive 
negative RCTs [3-7], however, enthusiasm for implemen-
tation of SGC has declined, hampering the translation of 
SGC into daily ICU practice.
Apart from the inﬂ  uence of the negative RCTs, several 
other factors may hinder implementation of SGC. Fear of 
severe hypoglycemia hindered, at least in part, broad 
imple  mentation of SGC [10]. Also, SGC mandates fre-
quent blood glucose measurements, which may be   con-
sidered labor intensive. In addition, although SGC in the 
two positive RCTs was solely applied by ICU nurses [1,2], 
it is often suggested that these caregivers lack suﬃ   cient 
background knowledge to safely apply SGC (in particular 
when aiming at the lower normal limits of blood glucose 
levels) [11].
Th  ere are several alternative explanations for why the 
ﬁ  ve negative RCTs of SGC showed no beneﬁ  cial eﬀ  ects. 
In addition, risks of severe hypoglycemia should be 
rationalized. And also one may wonder whether SGC is 
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apart from the possibility that SGC may indeed 
not benefi  t ICU patients. These include, but are not 
restricted to, variability in the performance of SGC, 
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attempt to explain the variances in outcomes of the RCTs 
of SGC and discuss the limitations of the current 
literature.
Glucose metabolism in the critically ill
Critical illness-induced hyperglycemia was long believed 
a beneﬁ  cial, adaptive response to provide those organs 
that predominantly rely on glucose as metabolic substrate 
(brain and blood cells) with additional energy. However, 
critical illness-induced hyperglycemia is also associated 
with adverse outcome [13-16]. Hyperglycemia has been 
suggested to be acutely toxic in critically ill patients 
because of accentuated cellular glucose overload and 
pronounced toxic side eﬀ  ects of glycolysis and oxidative 
phosphorylation [17]. During severe illness, the expres-
sion of glucose transporters on the membranes of several 
cell types is upregulated, which during reperfusion after 
ischemia may allow high circulating glucose levels to 
overload and damage these cells. Besides cellular glucose 
overload, vulnerability to glucose toxicity may be due to 
increased generation of and/or deﬁ  cient  scavenging 
systems for reactive oxygen species produced by activated 
glycolysis and oxidative phosphorylation.
In the context of threatened organ function due to 
critical illness, hyperglycemia-induced cellular injury 
could reﬂ   ect a preventable risk. Establishing a causal 
relationship between hyperglycemia and adverse 
outcomes, however, requires RCTs to assess the impact 
of preventing and/or treating hyperglycemia in critically 
ill patients.
Glycemic control aiming at normoglycemia
Randomized controlled trials on strict glycemic control
Table 1 presents a summary of the RCTs reported to date 
on SGC. Th  e ﬁ   rst single-center RCT from Leuven 
showed SGC to signiﬁ   cantly decrease mortality in 
surgical ICU patients (4.6% in the interven  tion group 
versus 8.0% in the control group) [1]. SGC also reduced 
the incidence of bloodstream infections, acute renal 
failure requiring dialysis or hemoﬁ  ltration,  red-cell 
transfusions and critical illness polyneuropathy. In 
addition, SGC was associated with a shorter time of 
ventilatory support. Th   e second single-center RCT from 
Leuven showed SGC to reduce morbidity, but not 
mortality in medical ICU patients [2]. Of note, the power 
analysis for this trial was based on the number of patients 
requiring ≥3 days of stay in the ICU. Since the trial 
recruited only 767 patients who stayed ≥3 days in the 
ICU, and not 1,200 patients as calculated in the power 
analysis, this trial was not powered to detect a diﬀ  erence 
in mortality in the intention to treat population. However, 
while no impact on in-hospital mortality was found in 
the intention to treat analysis (37.3% in the intervention 
group versus 40.0% in the control group), a per protocol 
analysis of patients who stayed in the ICU ≥3 days did 
show a diﬀ  erence in mortality (43.0% in the intervention 
group versus 52.5% in the control group).
A Saudi Arabian single-center RCT revealed no 
signiﬁ  cant  diﬀ   erence in ICU mortality (13.5% in the 
intervention group versus 17.1% in the control group) [3]. 
Also, after adjustment for baseline characteristics, SGC 
was not associated with a mortality diﬀ   erence. In a 
Colombian single-center RCT, 28-day mortality rate was 
not aﬀ  ected by SGC (36.6% in the intervention group 
versus 32.4% in the control group) [4]. Also, ICU 
mortality was not diﬀ  erent between study groups in this 
trial. A German multi-center RCT, in which patients with 
severe sepsis were randomly assigned to receive either 
SGC or conventional therapy and either 10% pentastarch, 
a low molecular weight hydroxyethyl starch, or modiﬁ  ed 
Ringer’s lactate for ﬂ   uid resuscitation, was stopped 
prematurely for safety reasons (increased incidence of 
severe hypoglycemia with SGC, higher rates of acute 
renal failure and need for renal-replacement therapy with 
pentastarch) [5]. At 28 and 90 days, there was neither a 
diﬀ  erence in mortality (24.7% and 39.7% in the inter  ven-
tion group versus 26.0% and 35.4% in the control group), 
nor a diﬀ   erence in the mean score for organ failure 
between the study groups. In a RCT from Australia/New 
Zealand and Canada, unexpectedly, 90-day mortality was 
even higher with SGC (27.5% in the intervention group 
versus 24.9% in the control group) [6]. Th  ere were no 
diﬀ   er  ences between the intervention group and the 
control group in the median number of days in the ICU 
or hospital, or the median number of days of mechanical 
ventilation or renal replacement therapy. Finally, a multi-
center RCT from Europe (Austria, Belgium, Spain, 
France, Italy, Slovenia, and the Netherlands) and Israel, 
which was stopped prematurely because of lack of diﬀ  er-
ence regarding blood glucose control, again SGC was not 
associated with mortality reduction (15.3% in the inter-
vention group versus 17.2% in the control group) [7].
Meta-analyses of randomized controlled trials of strict 
glycemic control
Two meta-analyses, of which the ﬁ  rst included the ﬁ  rst 
ﬁ  ve RCTs [18], and the second all trials except the last 
RCT [19], showed SGC not to be associated with signi  ﬁ  -
cantly reduced hospi    tal mortality. However, diﬀ  erent 
primary outcome measures were used in the successive 
RCTs (that is, 28-day mortality, 90-day mortality, ICU 
mortality and/or hospital mortality). Th   is is not a trivial 
comment, since, for instance, discharge criteria and 
follow-up beyond ICU and hospital discharge may vary 
and, as such, may have aﬀ  ected outcome. Th  is makes 
correct interpretation of the meta-analyses diﬃ   cult,  if 
not impossible.
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of strict glycemic control - grading the evidence
Th   ere are several alternative explanations for why the ﬁ  ve 
negative RCTs do not show beneﬁ  cial eﬀ  ects of SGC, 
apart from the possibility that SGC may indeed not 
beneﬁ  t ICU patients. Th   ese include, but are not restricted 
to, variability in the performance of SGC, diﬀ  erences 
between trial designs, changes in standard of care, 
diﬀ  erences in timing (that is, initiation) of SGC, and the 
convergence between the intervention groups and 
control groups with respect to achieved blood glucose 
levels in the successive RCTs.
Variability in the performance of strict glycemic control
SGC may seem an easy to implement strategy, but there 
are several aspects of SGC that might be important and 
are frequently overlooked [20]. Indeed, SGC is a complex 
intervention that involves several sequential steps that 
may all contain potential sources of variability (Figure 1).
In the two positive RCTs from Leuven, ICU nurses 
were using accurate blood gas analyzers to measure 
blood glucose in arterial blood at strict time points, and 
in between those time points whenever deemed 
necessary. Notably, in the second RCT from Leuven a 
variety of glucose analyzers were used, not just blood gas 
analyzers. SGC comprised a reliable continuous infusion 
of insulin exclusively via a central venous line, using 
accurate syringe-driven infusion pumps. Delicate insulin 
dose adaptations were to be performed exclusively by 
ICU nurses who were especially trained to implement 
this complex strategy (that is, executing insulin dose 
adaptations), while based on a guideline, aiming for blood 
glucose levels close to the lower normal limit, and also 
requiring a high level of intuitive decision making. And, 
ﬁ  nally, patients were kept in a non-fasting state at all 
times - glucose was administered on the ﬁ  rst day, and 
thereafter balanced enteral nutrition, supplemented 
where needed by parenteral nutrition, was provided 
during the entire stay in the ICU.
Several of the above mentioned methodological aspects 
of SGC often diverged substantially in successive RCTs. 
Indeed, blood glucose levels could be checked using 
capillary whole blood samples, using less accurate 
glucose analyzers [3-7]. Notably, this was also the case in 
the second RCT from Leuven - this may be one of the 
reasons that the rate of severe hypoglycemia was so much 
higher in this trial. Instead of accurate syringe-driven 
infusion pumps, volumetric infusion pumps could be, or 
were exclusively, used [3,4], or this was not mentioned 
[7]. Also, training of ICU nurses in the guideline was 
either not mentioned (and thus possibly not done in a 
structured way) [5,7], or seemed to be restricted to 
Table 1. Randomized controlled trials on strict glycemic control (target blood glucose levels of 80 to 110 mg/dl)
Main results of the trial Do results 
support the 
use of SGC? Reference Year What was compared? Study population Mortality Severe hypoglycemia
van den Berghe 
et al. [1]
2001 SGC versus standard   therapy 
(target blood glucose level 
of 180 to 200 mg/dl if 
exceeded 215 mg/dl)
1,548 surgical critically 
ill patients
SGC decreased mortality 
(4.6 versus 8.0%)
SGC raised the incidence 
of severe hypoglycemia 
(5.1 versus 0.8%)
Yes
van den Berghe 
et al. [2]
2006 SGC versus standard therapy 
(target blood glucose level 
of 180 to 200 mg/dl if 
exceeded 215 mg/dl)
1,200 medical critically 
ill patients
SGC decreased mortality of 
patients who stayed in ICU 
≥3 days (43.0 versus 52.2%)
SGC raised the incidence 
of severe hypoglycemia 
(18.7 versus 3.1%)
Yes
Arabi et al. [3] 2008 SGC versus standard therapy 
(target blood glucose level 
of 180 to 200 mg/dl)
523 mixed medical-
surgical critically ill 
patients
SGC did not aff  ect ICU 
mortality (13.5% versus 
17.1%)
SGC raised the incidence 
of severe hypoglycemia 
(28.6 versus 3.1%)
No
De la Rosa 
et al. [4]
2008 SGC versus standard therapy 
(target blood glucose level 
of 180 to 200 mg/dl)
504 mixed medical-
surgical critically ill 
patients
SGC did not aff  ect 28-day 
mortality (36.6% versus 
32.4%)
SGC raised the incidence 
of severe hypoglycemia 
(8.5 versus 1.7%)
No
Brunkhorst 
et al. [5]
2008 SGC versus standard therapy 
(target blood glucose level 
of 180 mg/dl if exceeded 
200 mg/dl)
488 mixed medical-
surgical critically ill 
patients
SGC did not aff  ect 28-day 
mortality (24.7 versus 26.0%); 
SGC did not aff  ect 90-day 
mortality (39.7 versus 35.4%)
SGC raised the incidence 
of severe hypoglycemia 
(17.0 versus 4.1%)
No
Finfer 
et al. [6]
2009 SGC (target blood glucose 
level of 81 to 108 mg/dl) 
versus standard therapy 
(target blood glucose level 
of <180 mg/dl)
6,104 mixed medical-
surgical critically ill 
patients
SGC did not aff  ect 28-day 
mortality (22.3 versus 20.8%); 
SGC increased 90-day 
mortality (27.5 versus 24.9%)
SGC raised the incidence 
of severe hypoglycemia 
(6.8 versus 0.5%)
No
Preiser 
et al. [7]
2009 SGC (target blood glucose 
level of 80 to 110 mg/dl) 
versus standard therapy (140 
to 180 mg/dl) 
1,101 mixed medical-
surgical critically ill 
patients
SGC did not aff  ect 28-day 
survival (17.2 versus 15.3%)
SGC raised the incidence 
of severe hypoglycemia 
(8.7 versus 2.7%)
No
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hypoglycemia [3]. It was either not stated whether ICU 
nurses exclusively titrated insulin, or it was stated that 
both ICU nurses and ICU physicians decided on insulin 
dose adaptations [5], which may be inappro  priate. And 
ﬁ   nally, glucose administration on the ﬁ   rst day was 
frequently not mentioned and thus probably not a part of 
the protocol [3,5,7].
Most challenging in this context, however, is the 
‘expertise-based control system’ as applied by the ICU 
nurses from Leuven. While the algorithm from Leuven 
contains no more than a set of simple rules (that is, there 
is an absence of explicit rules, such as present in closed-
loop systems, computer-based decision support systems, 
and paper-based systems using sliding scales), it required 
a high level of intuitive decision making by its users. It is 
diﬃ     cult, if not impossible, to identify the speciﬁ  c 
elements of this ‘intuitive control system’ that contributed 
to the outcome observed in the trials from Leuven. Th  e 
same may apply for the skill and motivation of ICU 
nurses from Leuven. Th   eir talent in implementing SGC, 
as well as motivation to apply it, may very well not have 
been copied in trials beyond their ICU. In this context it 
is important to note that the interventional arms of some 
of the multi-center RCTs contained very low numbers of 
patients. For instance, the German multi-center RCT 
included 247 patients from 18 centers, which means that 
only 14 patients were in the interventional arm of the 
study in each center [5]. A similar calculation for the 
European multi-center RCT suggests that only 26 patients 
from each center were in the interventional arm [7]. It 
can also be questioned whether the practitioners in these 
trials were truly skilled in SGC.
We consider all these diﬀ  erences from the two positive 
RCTs to be potentially responsible, at least in part, for the 
diverse outcomes of the ﬁ  ve negative RCTs. As indicated 
in Figure 1, methodological aspects of SGC can be scored 
from relatively ‘easy’, ‘simple’, ‘distinct’ and/or ‘clear’ to 
‘obscure’, ‘indistinct’, ‘complex’ and/or ‘diﬃ   cult’  with 
regard to translation from one ICU (or study) to another 
Figure 1. Methodological aspects of strict glycemic control, which may contain potential sources of variability in the performance of 
this strategy. Items are categorized into the following subjects: ‘monitoring’, ‘insulin delivery’, ‘algorithm’, and ‘experience’. Items are also roughly 
positioned on a line from ‘easy’, ‘simple’, ‘distinct’ and/or ‘clear’ to implement towards ‘obscure’, ‘indistinct’, ‘complex’ and/or ‘diffi   cult’ to translate from 
one center to another. Specifi  c elements per item indicated with an asterisk are as performed in the single-center RCTs from Leuven. SGC, strict 
glycemic control.
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monitoring are easily made, simple, distinct and clear; 
whereas an intuitive control system for SGC is obscure, 
indistinct, very complex and diﬃ   cult, if not impossible to 
translate into another setting. All other aspects can be 
scored in between these extremes.
Study design
One issue with the three smaller RCTs is that they were 
all statistically underpowered to detect a reasonable 
mortality diﬀ  erence [3-5]. Especially the early termina-
tion of the German study was rather inopportune [5]: 
while this study performed best in the intervention 
group, with blood glucose levels closer to the upper limit 
of SGC than the other negative trials, the study protocol 
allowed for early termination because of safety. Th  e 
increase in the incidence of severe hypoglycemia forced 
the investigators to stop the study, leaving us with under-
powered trial results. Although the last RCT speciﬁ  cally 
addressed the issue of statistical power, this trial was 
possibly also underpowered, as outlined below.
Change in standard of care
Glycemic control has changed over the past decade. A 
policy of insulin therapy to target lower blood glucose 
levels has been adopted in many ICUs since the publica-
tion of the ﬁ  rst RCT of SGC [1]. Accordingly, SGC was 
compared with distinct ‘control’ targets (Figure  2). 
Indeed, in all the trials except for two, glycemic control 
had improved in the control group when compared to the 
ﬁ  rst RCT. In addition, an increase was noticed in the 
number of patients who received insulin, or there was an 
increase in the amount of infused insulin in the control 
group [2-7]. Th  is diversity makes the successive trials 
fundamentally diﬀ  erent from the ﬁ  rst RCT. Indeed, these 
RCTs were executed in the ‘ﬂ  attened’ part of the observed 
blood glucose level-mortality risk curve [13]. Th  e  hypo-
the sized  eﬀ  ect size in the last two RCTs [6,7] (3 to 4% 
absolute reduction in risk of death, similar to what was 
observed in the original two RCTs [1,2]) was, therefore, 
too optimistic: according to the pooled analysis of the 
original two RCTs [21], the absolute reduction in mor-
tality that could have been expected from further lower-
ing blood glucose levels compared to the standard care 
level was only roughly 1%. Th   is would mean that tens of 
thousands of patients would be needed to show this eﬀ  ect 
in a multi-center setting (and not thousands of patients, 
as in the RCT from Australia/New Zealand and Canada 
[6]).
Timing of the intervention
In most trials time till reaching the preset blood glucose 
level target is insuﬃ     ciently reported. When time till 
target is too long, the time window for prevention of 
toxicity of hyperglycemia may have passed and irrever-
sible damage may already have occurred [22]. Th  is 
pheno  menon has also been suggested by the pooled 
analysis of the two original RCTs [21]. Th  e time lag 
between onset of hyperglycemia (which is usually present 
on admission to ICU) and the time that blood glucose 
levels are within the target range may depend on several 
factors, including a delay in identifying eligible patients, 
randomization and initiation of SGC, the SGC algorithm 
itself, and the quality of its implementation. All these 
factors could be an issue of study design. Of note, for one 
RCT we can conclude this to be an important factor, as 
Figure 2. Blood glucose levels (mean or median in the control or conventional group (closed bars) and strict glycemic control group 
(open bars) of seven randomized controlled trials. Original single-center randomized controlled trials (RCTs) from Leuven [1,2]; single-center 
RCTs [3,4]; multi-center RCTs [5-7]. Dotted lines indicate the blood glucose levels in the two original single-center RCTs from Leuven.
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13 hours because of randomization [6].
Achieved blood glucose levels
It is notable that none of the RCTs completed after the 
two original trials managed to achieve the strict degree of 
glycemic control achieved by the Leuven investigators 
[1,2]. Indeed, no trial had a median or mean blood 
glucose level in the intervention group below the upper 
normal target of blood glucose (Figure 2). Of note, one 
meta-analysis suggests that studies that managed to 
achieve the blood glucose target showed a reduced 
mortality whereas studies that did not succeed in 
reaching the target reported no beneﬁ   t or even an 
increased mortality [19]. Th  is ﬁ   nding underlines that 
SGC, though basically simple, is not an easy to implement 
strategy.
Uncertain factors
Other, yet uncertain factors may explain the divergent 
trial results, for instance, the variability of blood glucose 
levels. SGC algorithms, if properly applied, should 
decrease both the mean blood glucose level and its 
variability. Recent studies showed signiﬁ  cant associations 
between variability of blood glucose levels and patient 
outcomes [23-25]. From personal experience we know 
that implementation of SGC takes considerable time. 
Variability of blood glucose levels in the multi-center 
RCTs, therefore, is not unlikely as some ICUs in these 
trials must have recruited only a limited number of 
patients  [5-7]. Variability of blood glucose levels has 
neither been studied and reported nor compared between 
the RCTs. Many other metrics of successful glycemic 
control exist, but were neither measured nor compared 
among the RCTs [26].
Implementation of SGC - rationalizing fears and 
consequences of a strict regimen
The issue of severe hypoglycemia
Severe hypoglycemia is a feared complication of SGC. 
Undoubtedly, with implementation of SGC the incidence 
of severe hypoglycemia increases. Reported incidences of 
severe hypoglycemia (blood glucose level <40 mg/dl) rise 
by ﬁ   ve- to ten-fold compared to conventional blood 
glucose control in RCTs (Table 1).
Neuroglycopenia may cause cerebral damage, epileptic 
insults or even coma [27]. However, how deep does hypo-
glycemia need to be, and how long its duration, to cause 
these eﬀ  ects [28]? In the former century, repeated epi-
sodes of insulin-induced hypoglycemic coma for periods 
ranging from 45 minutes to 3 hours for the treatment of 
opiate addiction and schizophrenia have been found to 
have minimal long-term eﬀ  ects and a mortality of less 
than 1% [29]. In addition, long-term follow up of patients 
with diabetes mellitus in large prospective trials failed to 
detect any association between the frequency of severe 
hypoglycemia and cognitive decline [30,31]. Only subtle, 
reversible impairments of attention could be detected in 
non-diabetic patients undergoing dynamic pituitary 
function assessment using hypoglycemic stress with 
blood glucose levels of 29 mg/dl [32].
At present we cannot conclude with certainty that 
severe hypoglycemia with SGC harms critically ill patients. 
Two retrospective studies identiﬁ   ed (severe) hypogly-
cemia as an independent predictor of mortality [13,33]. 
However, 30% of patients with severe hypoglycemia in 
one of the above cited retrospective studies were not on 
insulin therapy in the preceding 12 hours, and only a 
minority of patients was on intravenous insulin therapy 
[33]. Th   erefore, this study hardly oﬀ  ers an answer to the 
question of whether severe hypoglycemia with SGC 
inﬂ   uences outcome. Similar problems exist with the 
interpretation of the results from the other retrospective 
study, in which the impact of early (that is, <24 hours 
after admission) hypoglycemia (not severe hypoglycemia) 
was studied. First, the occurrence of hypoglycemia may 
very well relate to severity of disease on admission. 
Second, the studied ICUs did not apply SGC [13]. Never-
theless, multivariable regression analysis of the second 
RCT of SGC in Leuven conﬁ  rmed that severe hypogly-
cemia was independently associated with mortality, and 
may have diminished the beneﬁ  t of the intervention [2].
Of interest, one experiment performed in rodents 
showed that brain damage was not associated with the 
duration of severe hypoglycemia, but instead with its 
correc  tion with intravenous dextrose, causing formation 
of radicals [34]. Indeed, brain damage correlated to the 
concentration and amount of dextrose used to correct 
severe hypoglycemia. Hypothetically, in practice, bolus 
glucose reperfusion of the depleted brain may cause more 
damage then the period of severe hypoglycemia itself. 
Finally, rapid administration of concentrated glucose 
solution for the correction of hypoglycemia may cause 
dangerous arrhythmias, potentially via hyperkalemia 
from the rapid administration of a concentrated glucose 
solution [35].
Which caregiver should be responsible for the 
implementation of SGC?
One ﬁ   nal question on SGC concerns who should be 
responsible for its implementation in daily practice? In 
the hospital where the two positive RCTs of SGC were 
performed, without doubt SGC was (and still is) a 
completely nurse-driven strategy without the interference 
of ICU physicians, who are not at the bedside as fre-
quently as ICU nurses [36]. Although several arguments 
plea for SGC being a nurse-driven strategy, one could 
argue that ICU nurses lack suﬃ   cient  background 
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blood glucose control aims at the lower limits of 
normoglycemia (that is, with an increased risk of severe 
hypoglycemia). Of similar importance may be the fact 
that ICU nurses may feel legally unprotected when 
applying SGC [10]. However, a nested case-control study 
revealed that many of the predisposing factors for hypo-
glycemia in ICU patients were in fact easy to recognize 
[37]. Predisposing factors included decreases of nutrition 
without adjustment for insulin infusion, sepsis, and 
changes in inotropic support. Th  ese are all earlier and 
better recognized by bedside ICU nurses than by ICU 
physicians taking care of many patients at the same time.
We cannot be certain whether inadequacies in 
perform  ing safe (that is, preventing severe hypoglycemia) 
and eﬀ  ective (that is, achieving the target) SGC is an 
important factor in explaining the diﬀ  erences between 
the positive and negative RCTs. However, as pointed out 
above, studies suggest that blood glucose variability does 
have an impact on outcome [25]. One advantage of 
nurse-driven SGC may be that there is less blood glucose 
variability, since ICU nurses can respond earlier to 
changes in the blood glucose level, and since ICU nurses 
can titrate insulin without the interference of ICU 
physicians, who are not at the bedside as frequently as 
ICU nurses.
Discussion and future perspectives
During critical illness, glucose should not be seen as an 
innocent bystander. Indeed, lowering blood glucose levels 
has the potential to prevent injury to already threatened 
vital organs. However, the optimum level as well as the 
optimal mode to reach that level still needs to be deﬁ  ned. 
Th   e observations that SGC exerted both positive [1,2] and 
negative eﬀ  ects [6] poses a fascinating impasse.
Of course, it should be recognized that the single-
center RCTs may have suﬀ  ered from several drawbacks. 
First, known, unknown and/or unrecognized diﬀ  erences 
between study settings may obstruct generalizability of 
results. Second, motivational eﬀ  ects of investigators can 
never be ruled out, in particular when investigators 
cannot be blinded. Such factors all apply to the single-
center trials on SGC. However, one may also argue from 
a methodological standpoint that the single-center design 
of the two original RCTs was preferable. It could be 
diﬃ     cult, if not impossible, to identify all important 
factors of this complex intervention that contributed to 
the outcome as observed in the RCTs from Leuven. In 
particular, poorly identiﬁ  ed factors, as discussed above, 
may not have been transferred to other ICUs. However, 
as such, the two original RCTs, as well as a third positive 
RCT of SGC in pediatric patients from the same 
investigators [38], remain to have internal validity but fail 
to have external validity. Nevertheless, rather than 
concluding that SGC does not beneﬁ   t critically ill 
patients based on the successive negative RCTs in other 
ICUs, we prefer ﬁ  rst to search for diﬀ  erences between the 
designs of the positive and negative RCTs.
Th  ere are several possible ways to go from here. We 
could accept the lack of evidence on the optimum level of 
glycemic control. Th  e currently available evidence from 
the seven RCTs does not allow us to conﬁ  dently make an 
overall recommendation. Indeed, the question of one 
optimal target for glycemic control in ICU patients 
remains unanswered. Consequently, any advice remains 
pragmatic: assess whether the hypothesized beneﬁ  t was 
realistic, assess whether statistical power was suﬃ   cient, 
assess the level of evidence of the studies, assess whether 
the tools to measure and control blood glucose were 
adequate, assess whether the targets were achieved, and 
ﬁ   nally assess whether the levels of glycemic control 
diverged relevantly. Clinicians should also determine 
how comparable the patients in the diﬀ  erent RCTs are to 
their own and decide on what is their best target for 
glycemic control.
Alternatively, we perform another RCT, using the same 
targets as in the positive RCTs [1,2], both for the 
interventional and the control groups. Th  is, however, 
may be unethical if not impossible for several reasons. 
First, standard of care regarding glycemic control has 
deﬁ  nitely changed over the past decade (that is, can we 
speak of ‘conventional’ therapy when targeting a higher 
threshold than commonly applied?). How to explain that 
we should perform a new trial in which we deliberately 
expose critically ill patients to the risks of hyperglycemia? 
On the other hand, one may say that the negative trials 
on SGC did not show that mild hyperglycemia harmed 
ICU patients (although in most trials hyperglycemia was 
less severe than in the two positive RCTs). However, one 
could also posit that it is unethical to discard the evidence 
from the two positive RCTs, and we are obliged to repeat 
this study.
Given the substantial evidence for the generation of 
harm from hyperglycemia [13-16] and the conﬂ  icting 
results from the seven RCTs [1-7], considerable work 
remains to be done in identifying the confounding factors 
in the clinical application of SGC. Th   is process needs to 
be explicit and systematic, and should at least include the 
points raised in this commentary. An individual patient 
data meta-analysis examining the discrepancies between 
studies may be a good start.  If new RCTs are to be 
performed, investigators should recognize the several 
shortcomings of the recent negative trials, as previously 
described. Most important, glucose levels in the 
intervention groups in any new trials should indeed reach 
targets between 80 and 110 mg/dl.
Perhaps one other step in this ﬁ  eld of ICU medicine 
will involve the next generation of (continuous or 
Schultz et al. Critical Care 2010, 14:223 
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ithm technology [39]. Th   ese may reduce the incidence of 
severe hypoglycemia, glycemic variability and the nursing 
work burden.
What should those caregivers do who want to imple-
ment this strategy? As outlined above, key aspects of 
SGC should be recognized: accurate blood gas analyzers 
to measure blood glucose in arterial blood at strict time 
points; reliable continuous infusion of insulin exclusively 
via a central venous line; accurate syringe-driven infusion 
pumps; insulin dose-adaptations performed exclusively 
by specially trained ICU nurses, with high levels of intuitive 
decision making; and non-fasting state at all times. Results 
from animal studies point us to potential risks associated 
with overcorrection of severe hypoglycemia.
Conclusion
While SGC decreased mortality and morbidity of adult 
critically ill patients in two RCTs, ﬁ  ve successive RCTs 
failed to show a beneﬁ  t of this strategy, with one trial 
even reporting unexpected higher mortality. Th  ere are 
several alternative explanations for the ﬁ  ve negative RCTs 
that showed no beneﬁ  cial eﬀ  ects of SGC, apart from the 
possibility that SGC may indeed not beneﬁ  t critically ill 
patients. Th   e currently available evidence from the seven 
RCTs, however, does not allow us to conﬁ  dently make an 
overall recommendation regarding glycemic control. 
Clinicians should determine how comparable the patients 
in the diﬀ  erent RCTs are to their own and decide on what 
is their best target for glycemic control. More RCT 
evidence is needed, but it is questionable whether there 
will ever be a new trial using the same targets as in the 
original RCTs.
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